

# Jan W Eriksson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3659752/jan-w-eriksson-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90  
papers

2,520  
citations

27  
h-index

48  
g-index

100  
ext. papers

3,240  
ext. citations

5.9  
avg, IF

5.22  
L-index

#	Paper	IF	Citations
90	Role of estrogen and its receptors in adipose tissue glucose metabolism in pre- and postmenopausal women.. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2022</b> ,	5.6	1
89	Individual goal-based plan based on nursing theory for adults with type 2 diabetes and self-care deficits: a study protocol of a randomised controlled trial.. <i>BMJ Open</i> , <b>2022</b> , 12, e053955	3	
88	Excess glucocorticoid exposure contributes to adipose tissue fibrosis which involves macrophage interaction with adipose precursor cells.. <i>Biochemical Pharmacology</i> , <b>2022</b> , 198, 114976	6	1
87	Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, ECells and Metabolome. <i>Metabolites</i> , <b>2021</b> , 11, 574	5.6	0
86	Positional and compositional analysis of saturated, monounsaturated, and polyunsaturated fatty acids in human adipose tissue triglyceride by C nuclear magnetic resonance. <i>NMR in Biomedicine</i> , <b>2021</b> , e4632	4.4	
85	Human macrophages stimulate expression of inflammatory mediators in adipocytes; effects of second-generation antipsychotics and glucocorticoids on cellular cross-talk. <i>Psychoneuroendocrinology</i> , <b>2021</b> , 125, 105071	5	2
84	Quality of life of type 2 diabetes mellitus patients in Ramallah and al-Bireh Governorate-Palestine: a part of the Palestinian diabetes complications and control study (PDCCS). <i>Quality of Life Research</i> , <b>2021</b> , 30, 1407-1416	3.7	0
83	Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. <i>Diabetes Care</i> , <b>2021</b> , 44, 1211-1218	14.6	5
82	Time Course of Metabolic, Neuroendocrine, and Adipose Effects During 2 Years of Follow-up After Gastric Bypass in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e4049-e4061	5.6	1
81	Tissue-specific glucose partitioning and fat content in prediabetes and type 2 diabetes: whole-body PET/MRI during hyperinsulinemia. <i>European Journal of Endocrinology</i> , <b>2021</b> , 184, 879-889	6.5	1
80	Altered hormonal and autonomic nerve responses to hypo- and hyperglycaemia are found in overweight and insulin-resistant individuals and may contribute to the development of type 2 diabetes. <i>Diabetologia</i> , <b>2021</b> , 64, 641-655	10.3	4
79	The Plasma Metabolomic Profile is Differently Associated with Liver Fat, Visceral Adipose Tissue, and Pancreatic Fat. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e118-e129	5.6	2
78	Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 75-85	6.7	16
77	Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes. <i>Obesity</i> , <b>2021</b> , 29, 535-542	8	2
76	Effects of Gastric Bypass Surgery on the Brain: Simultaneous Assessment of Glucose Uptake, Blood Flow, Neural Activity, and Cognitive Function During Normo- and Hypoglycemia. <i>Diabetes</i> , <b>2021</b> , 70, 1265-1277	9.9	5
75	Macrophage-derived secretome is sufficient to confer olanzapine-mediated insulin resistance in human adipocytes. <i>Comprehensive Psychoneuroendocrinology</i> , <b>2021</b> , 7, 100073	1.1	3
74	Metformin as an anti-inflammatory agent: a short review. <i>Journal of Endocrinology</i> , <b>2021</b> , 251, R11-R22	4.7	5

73	A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTTEST): Rationale, design and protocol. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107996	3.2	1
72	Integration of whole-body [F]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes. <i>Scientific Reports</i> , <b>2020</b> , 10, 8343	4.9	2
71	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1607-1618	6.7	38
70	Sleep apnea in men is associated with altered lipid metabolism, glucose tolerance, insulin sensitivity, and body fat percentage. <i>Endocrine</i> , <b>2020</b> , 70, 48-57	4	6
69	A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1157-1166	6.7	17
68	Rapid changes in neuroendocrine regulation may contribute to reversal of type 2 diabetes after gastric bypass surgery. <i>Endocrine</i> , <b>2020</b> , 67, 344-353	4	13
67	Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population. <i>World Journal of Hepatology</i> , <b>2020</b> , 12, 149-159	3.4	9
66	Long-term follow-up of antivasular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study. <i>Acta Ophthalmologica</i> , <b>2020</b> , 98, 360-367	3.7	1
65	Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes. <i>Molecular and Cellular Endocrinology</i> , <b>2020</b> , 503, 110696	4.4	15
64	Proof-of-concept for CRISPR/Cas9 gene editing in human preadipocytes: Deletion of FKBP5 and PPAR $\gamma$ and effects on adipocyte differentiation and metabolism. <i>Scientific Reports</i> , <b>2020</b> , 10, 10565	4.9	9
63	Quality of life after gastric bypass surgery in patients with type 2 diabetes: patients' experiences during 2 years of follow-up. <i>Diabetology and Metabolic Syndrome</i> , <b>2020</b> , 12, 90	5.6	
62	Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism. <i>Psychoneuroendocrinology</i> , <b>2019</b> , 110, 104445	5	14
61	Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. <i>Drugs</i> , <b>2019</b> , 79, 219-230	12.1	82
60	Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2601-2613	5.6	14
59	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 515-527	18.1	99
58	Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?. <i>Frontiers in Physiology</i> , <b>2019</b> , 10, 457	4.6	16
57	Estrogen interacts with glucocorticoids in the regulation of lipocalin 2 expression in human adipose tissue. Reciprocal roles of estrogen receptor $\alpha$ and $\beta$ in insulin resistance?. <i>Molecular and Cellular Endocrinology</i> , <b>2019</b> , 490, 28-36	4.4	12
56	Plasma metabolomic patterns in patients with exhaustion disorder. <i>Stress</i> , <b>2019</b> , 22, 17-26	3	6

55	Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2651-2659	6.7	8
54	Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner. <i>Uppsala Journal of Medical Sciences</i> , <b>2019</b> , 124, 158-167	2.8	2
53	Intra- and inter-individual metabolic profiling highlights carnitine and lysophosphatidylcholine pathways as key molecular defects in type 2 diabetes. <i>Scientific Reports</i> , <b>2019</b> , 9, 9653	4.9	18
52	Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery. <i>European Journal of Endocrinology</i> , <b>2019</b> , 181, 161-171	6.5	7
51	Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1136-1145	6.7	42
50	Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 193-201	5.6	21
49	Calcineurin is an important factor involved in glucose uptake in human adipocytes. <i>Molecular and Cellular Biochemistry</i> , <b>2018</b> , 445, 157-168	4.2	9
48	Whole-Body Imaging of Tissue-specific Insulin Sensitivity and Body Composition by Using an Integrated PET/MR System: A Feasibility Study. <i>Radiology</i> , <b>2018</b> , 286, 271-278	20.5	19
47	Complications of type 2 diabetes mellitus in Ramallah and al-Bireh: The Palestinian Diabetes Complications and Control Study (PDCCS). <i>Primary Care Diabetes</i> , <b>2018</b> , 12, 547-557	2.4	10
46	Secretagogin is increased in plasma from type 2 diabetes patients and potentially reflects stress and islet dysfunction. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196601	3.7	10
45	FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes. <i>Endocrine</i> , <b>2018</b> , 62, 116-128	4	32
44	Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover. <i>Adipocyte</i> , <b>2018</b> , 7, 285-296	3.2	1
43	Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study. <i>Hormone and Metabolic Research</i> , <b>2018</b> , 50, 627-639	3.1	23
42	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006-2014. <i>PharmacoEconomics - Open</i> , <b>2018</b> , 2, 393-402	2.1	11
41	A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1511-1532	3.6	9
40	Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 344-351	6.7	124
39	Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study. <i>Hormone and Metabolic Research</i> , <b>2018</b> , 50, e10	3.1	4
38	Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2018</b> , 1, e00036	2.7	18

37	Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 1390-1403.e4	4.9	32
36	Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? <i>Diabetes Care</i> 2018;41:6-10. <i>Diabetes Care</i> , <b>2018</b> , 41, e104-e105	14.6	2
35	Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. <i>Diabetologia</i> , <b>2018</b> , 61, 1923-1934	10.3	160
34	Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 831-841	6.7	60
33	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1276-1288	6.7	37
32	Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 123, 199-208	7.4	35
31	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 864-876	18.1	174
30	Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 709-717	18.1	208
29	Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 49-60	6.7	52
28	Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. <i>Endocrine</i> , <b>2017</b> , 55, 839-852	4	26
27	Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers. <i>Uppsala Journal of Medical Sciences</i> , <b>2017</b> , 122, 234-242	2.8	4
26	Gastric Bypass Reduces Symptoms and Hormonal Responses in Hypoglycemia. <i>Diabetes</i> , <b>2016</b> , 65, 2667-759		42
25	Lipocalin 2 produces insulin resistance and can be upregulated by glucocorticoids in human adipose tissue. <i>Molecular and Cellular Endocrinology</i> , <b>2016</b> , 427, 124-32	4.4	24
24	Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up. <i>Diabetes and Vascular Disease Research</i> , <b>2016</b> , 13, 183-91	3.3	2
23	Alterations in heart rate variability during everyday life are linked to insulin resistance. A role of dominating sympathetic over parasympathetic nerve activity?. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 91	8.7	18
22	Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 998-1006	12.7	13
21	Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. <i>Diabetologia</i> , <b>2016</b> , 59, 1692-701	10.3	70
20	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. <i>Diabetes Research and Clinical Practice</i> , <b>2016</b> , 117, 39-47	7.4	49

19	Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting. <i>Diabetes Research and Clinical Practice</i> , <b>2016</b> , 121, 157-165	7.4	25
18	Impaired adipose tissue lipid storage, but not altered lipolysis, contributes to elevated levels of NEFA in type 2 diabetes. Degree of hyperglycemia and adiposity are important factors. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 1768-1780	12.7	36
17	Evaluation of reference genes for gene expression studies in human brown adipose tissue. <i>Adipocyte</i> , <b>2015</b> , 4, 280-5	3.2	11
16	A randomised wait-list controlled clinical trial of the effects of acceptance and commitment therapy in patients with type 1 diabetes: a study protocol. <i>BMC Nursing</i> , <b>2015</b> , 14, 61	3.2	7
15	Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E1885-94	5.6	39
14	Short and long term in vivo effects of Cyclosporine A and Sirolimus on genes and proteins involved in lipid metabolism in Wistar rats. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 702-15	12.7	14
13	Cyclosporine A enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks of treatment. <i>Biochemical Pharmacology</i> , <b>2014</b> , 91, 61-73	6	10
12	FKBP5 expression in human adipose tissue increases following dexamethasone exposure and is associated with insulin resistance. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 1198-208	12.7	54
11	Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 29881-91	5.4	46
10	Positron emission tomography ligand [ <sup>11</sup> C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas. <i>Diabetes</i> , <b>2014</b> , 63, 3428-37	0.9	53
9	Differences between men and women in the regulation of adipose 11βHSD1 and in its association with adiposity and insulin resistance. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 1056-60	6.7	8
8	The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue. <i>Molecular and Cellular Endocrinology</i> , <b>2013</b> , 365, 260-9	4.4	54
7	mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 355, 96-105	4.4	69
6	Neuroendocrine mechanisms in insulin resistance. <i>Molecular and Cellular Endocrinology</i> , <b>2009</b> , 297, 104-114	11.4	24
5	Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. <i>Obesity</i> , <b>2005</b> , 13, 717-28		71
4	Insulin receptor substrates-1 and -2 are both depleted but via different mechanisms after down-regulation of glucose transport in rat adipocytes. <i>Endocrinology</i> , <b>2005</b> , 146, 3044-51	4.8	22
3	Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). <i>Diabetes Care</i> , <b>2003</b> , 26, 2903-9	14.6	82
2	Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 419-29	6.5	115

1 Organ-specific metabolic pathways distinguish prediabetes, type 2 diabetes and normal tissues

1